AstraZeneca (NASDAQ: AZN) has entered into a drug discovery collaboration and licensing agreement with insitro, an artificial intelligence therapeutics company, according to a company statement dated October 15, 2026.

The collaboration will use AI systems to identify drug targets and develop therapeutics for metabolic dysfunction-associated steatohepatitis (MASH) and cardiomyopathies.